Deal Globally, Treat Locally: Serono Buys Rights to InDex's Kappaproct
Executive Summary
In-licensing Phase II ulcerative colitis drug Kappaproct from Swedish biotech InDex Pharmaceuticals wasn't the major move observers have been waiting for from Serono; it certainly doesn't reduce the Swiss firm's dependence on Rebif. But the $35 million deal endorses InDex's localized approach to antisense therapy, a failure-ridden area that many firms have given up on.
You may also be interested in...
Gilead's Metamorphoses
Founded to pursue antisense, Gilead recognized that antisense was too long-term to support the continual financings they knew would be necessary to create a self-sustaining drug business. Thus Gilead began a series of transformations, eventually crafting an image for itself as a near-term antiviral company. Sidebar: Isis Stays Pure: As Gilead has shape-shifted into an antiviral player, Isis has continued to carry the antisense torch. And, says Stanley Crooke, MD, PhD, the company's CEO, Isis' develop
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.